Stay updated on Ravulizumab Study in LN/IgAN Clinical Trial
Sign up to get notified when there's something new on the Ravulizumab Study in LN/IgAN Clinical Trial page.

Latest updates to the Ravulizumab Study in LN/IgAN Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated to v3.4.2; the lapse-in-government funding notice and the prior revision reference (v3.4.1) were removed.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a government funding notice about site status and that the NIH Clinical Center is open; updated Revision: v3.4.1 and removed Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedResults for SANCTUARY (NCT04564339) were posted on 2026-01-22, including Week 26 and Week 50 proteinuria and eGFR outcomes for LN and IgAN cohorts; several previously listed result metrics were removed.SummaryDifference3%

- Check42 days agoChange DetectedThe page now displays 'Results Submitted' instead of 'No Results Posted' and the revision version updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check64 days agoChange DetectedLocations sections are consolidated under a single 'Locations' heading with updated states/countries; the HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.SummaryDifference0.9%

- Check85 days agoChange DetectedRevision: v3.3.2 appears on the page, replacing v3.3.1; this is a minor site maintenance update and does not alter study details or how to use the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Ravulizumab Study in LN/IgAN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ravulizumab Study in LN/IgAN Clinical Trial page.